About DeepCell
Deepcell is a life sciences technology company that combines artificial intelligence, high-resolution imaging, and microfluidics to decode cell identity and function through morphology. The company's flagship REM-I platform represents a breakthrough in single-cell analysis, enabling label-free imaging, AI-powered characterization, and gentle enrichment of viable cells based on their physical characteristics. At the heart of the platform is Deepcell's Human Foundation Model (HFM), a self-supervised AI trained on billions of single-cell images that extracts a 115-dimensional embedding from every brightfield cell image in real-time. This foundation model captures both human-interpretable morphological features and deeper patterns invisible to the eye, requiring no bespoke training for new applications or sample types. The platform combines high-speed, high-resolution brightfield imaging with gentle microfluidics for 6-way sorting, ensuring cells remain minimally perturbed and viable for downstream analysis. Deepcell pioneered the field of "morpholomics" — the high-dimensional, label-free study of cell morphology as a quantifiable data layer on par with genomics, transcriptomics, and proteomics. The company serves researchers across oncology, drug discovery, cell and gene therapy, regenerative medicine, transplant monitoring, and other areas of cell science. The integrated AXON data suite provides cloud and on-premises solutions for data visualization, analysis, and storage, enabling researchers to gain actionable insights within minutes without bioinformatics support. Founded from research at Stanford University, Deepcell continues to push the boundaries of cell science by revealing insights that no molecular marker or label could predict.
Mission & Story
Mission
We combine AI and high-resolution imaging to decode cell identity and function, empowering scientists to see biology as it truly is.
Founding Story
From the early days within the labs of Stanford University, alongside the best and brightest individuals dedicated to biological discoveries, Deepcell has had an unwavering drive to enable scientific knowledge. The company was founded by Maddison Masaeli and Mahyar Salek, who bridged the domains of life science, data and technology to extract actionable insights through the lens of cell morphology.
Clinical Focus
Medical conditions and clinical areas addressed by DeepCell.
Who It Serves
Milestones & Awards
Recent Milestones
Launch of REM-I OnSite (April 2026) for fully on-premises deployment in regulated and data-sensitive environments. Multiple pre-prints published on cancer cell diversity, sinonasal malignancy detection, and morphological applications. Attendance at AACR 2026 with keynote featuring Deepcell technology.
Key Partnerships
Social & Media
Follow on
Latest Updates
Company Details
- Headquarters
- Menlo Park, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.